In Jan. 2016, $PYPL's BoD authorized a stock repurchase program to repurchase up to $2Bil of common stock, with no expiration from the date of authorization. This program is intended to offset the impact of dilution from equity compensation programs and may be used to make repurchases of common stock to reduce outstanding share count.
$PRGO said that in the Consumer Healthcare business, it has been seeing certain pricing pressure. Therefore, across categories $PRGO competes in, it has competitive pricing. The company expects pricing pressure to continue in different segments going forward. But given the growth in new products, $PRGO expects to overcome the pricing challenges.
$PCLN is pleased with the top line strength in its forecast. There
is some pressure on the bottom line in 1Q17 where the company gets the gross
bookings and incurs the advertising expense but a significant portion is going
to check out in 2Q17 and 3Q17 and beyond when travel occurs. $PCLN expects the
gross bookings to turn into gross profits.
For 2017, in the Rx segment, $PRGO expects to launch more than five products with branded sales of greater than $800MM. In the CAC International segment, the company expects approx. $1.4Bil in 2017 net sales, while operating margin percentage in the segment is expected in the low teens.